FGFR-Mutant Bladder Cancer Biomarker Research Study with Erdafitinib Treatment

Unknown NCT05052372

Study Description

This biomarker research study is for patients with FGFR-mutant bladder cancer receiving erdafitinib standard of care treatment. The purpose is to investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations in cell-free tumor DNA. Patients co-enroll in an observational research study and consent to provide xCures right of access to their full medical records under HIPAA. Patient clinical data is structured and centralized by xCures in a CFR Part 11-compliant database in Case Report Forms. The data is abstracted directly from medical records generated in the standard practice of medicine and the results are undetermined.

Study Details

Registry ID:
NCT05052372
Conditions:
Bladder Cancer, Urothelial Carcinoma, Transitional Cell Carcinoma, Platinum-Resistant Urothelial Carcinoma, Bladder Urothelial Carcinoma, FGFR Mutation, FGFR2 Gene Mutation, FGFR3 Gene Mutation, FGFR2 Amplification, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Carcinoma, Refractory Bladder Urothelial Carcinoma
Phase:
Target Enrollment:
2 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →